Dr. Andreas Fouras
BEng, MEngSc(Res), PhD, MAICD
BEng, MEngSc(Res), PhD, MAICD
Inventor. Scientist. CEO.
Dr. Andreas Fouras
Accelerating the commercialisation of 4DMedical’s innovations globally
Andreas is the Founder, Managing Director, and Chief Executive Officer of 4DMedical (ASX:4DX), a medical technology company based in Australia and the United States. 4DMedical has developed X‑ray Velocimetry (XV) Lung Ventilation Analysis Software, based on the company’s proprietary XV Technology, which enables new levels of non-invasive, quantitative imaging and analysis of lung function.
Pioneered non-invasive lung imaging as Founder of 4DMedical (ASX:4DX).
Advanced breakthrough research in fluid dynamics and medical imaging.
Invented XV Technology with more than 100 papers and over 40 patents.
XV Technology quantifies functional lung impairment on fluoroscopy exams and provides ventilation reports
4DMedical is an Australian-based medical technology company, commercialising four-dimensional lung imaging solutions.
4DMedical was incorporated in 2012 to acquire imaging platform, XV Technology™, and associated intellectual property, from Monash University where it was originally conceived in 2005 and developed by Dr Andreas Fouras and his former research group.
4DMedical’s XV Technology™ is the first FDA cleared respiratory imaging solution that utilises mathematical models and algorithms to convert sequences of X-ray images into four-dimensional quantitative data. XV Technology™ is the result of over 15 years of development and published preclinical and clinical studies. The technology has been extensively patented, with core patents granted in key jurisdictions including the United States and Australia.
4DMedical’s CT:VQ™ earned FDA 510(k) clearance in September 2025, marking it as the first and only non-contrast ventilation–perfusion (V/Q) imaging solution.
CT:VQ™ is poised to redefine accessibility and efficiency in functional lung imaging.
“CT:VQ™ gives clinicians all the contrast, and none of the injections… the word ‘breakthrough’ is overused, but we believe the unprecedented capabilities of CT:VQ™ qualify for that description.”
Dr Andreas Fouras
4DMedical Founder, Managing Director and CEO
4DMedical’s CT:VQ™
Zero radioisotopes - no injected contrast
The first and only technology offering ventilation & perfusion imaging from existing non-contrast CTs.
Normal lung function
Subacute pulmonary embolism
“Better information leads to better decisions, and better decisions lead to better healthcare outcomes”
Dr Andreas Fouras
4DMedical Founder, Managing Director and CEO
Commercialising a global MedTech company
Andreas is the Founder, Managing Director and Chief Executive Officer of 4DMedical (ASX:4DX), a medical technology company, based in Australia and the United States. 4DMedical created X-ray Velocimetry Lung Ventilation Analysis Software based on the company’s proprietary XV Technology that enable new levels of non-invasive, quantitative imaging and analysis of lung function.
Leading breakthrough research in imaging and fluid dynamics
Andreas started his career in academic research studying experimental fluid dynamics in the Department of Mechanical and Aerospace Engineering at Monash University in Melbourne, Australia. His early research in wind tunnel quantification placed him as a young leader in the area of imaging (within fluid dynamics) developing a number of new approaches to the imaging of gas and liquid flow.
Earning global recognition as a professor and research innovator
Completing a Masters and PhD, and then rising to the position of Professor of Mechanical and Aerospace Engineering and Director of the Laboratory for Dynamic Imaging, Andreas was recognised by various accolades from a wide range of premier research bodies including the National Health and Medical Research Council and the American Asthma Foundation.
Translating scientific innovation into clinical technology
Andreas was able to apply a novel concept to clinical use through the development of XV Technology, uniquely measuring airflow within the breathing lungs, at every stage of the breath, with both high spatial and temporal resolution at low radiation dose. Andreas’ research has been documented in over 100 peer reviewed publications and over 40 patents and patent applications. Andreas founded 4DMedical in December 2012 from a desire for his work to reach and positively influence as many people globally as possible.
Driving commercialisation and leadership at scale
A recognised leader, as evidenced by an Australian Davos Connection Australian Leadership Award (2013), Andreas is now dedicated to applying his business acumen, drive and innovation to the commercialisation of 4DMedical’s technologies.